Authors
Brian Gelblung, Diana Montoya, Eduardo Beccar Varela, Julia Barber, Brian Morris, Belen Rodriguez Del Busto, Eunice Spengler, Pamela Garcia Suarez, Victoria Pousa, Federico Piñero, Ignacio McLean
Published in
Breast care (Basel, Switzerland). Apr 28, 2026. Epub Apr 28, 2026.
Abstract
Breast-conserving surgery (BCS) is traditionally avoided in multifocal or multicentric (MF/MC) breast cancer due to concerns about oncologic outcomes. Recent evidence suggests BCS may be feasible in selected cases. This study compared outcomes of BCS in MF/MC versus unifocal (UF) breast cancer.
This retrospective cohort included women with stage I-II breast cancer treated with BCS at a single institution in Argentina (2000-2023). Patients with prior neoadjuvant chemotherapy, pathogenic germline mutations, or extensive nodal disease were excluded. Outcomes were locoregional recurrence (LRR), distant recurrence (MTS), and overall survival (OS), analyzed with Kaplan-Meier estimates and Cox regression.
Of 1,188 patients undergoing BCS, 91 (7.7%) had MF/MC and 1,097 (92.3%) UF tumors. Median follow-up was 4.9 years. The 5-year cumulative probability of LRR was 3.8% overall; 3.3% in MF/MC; and 5.9% in UF patients (HR 1.04, 95% CI: 0.33-3.33; p = 0.94). Distant recurrence occurred in 3.3% of MF/MC and 4.8% of UF cases (HR 1.16, 95% CI: 0.36-3.73; p = 0.80). Five-year OS was 98.6% in MF/MC and 97.3% in UF patients (HR 1.25, 95% CI: 0.30-5.20; p = 0.76).
In this large single-institution cohort, BCS achieved comparable oncologic outcomes in MF/MC and UF breast cancer, supporting its feasibility in appropriately selected patients. These results provide real-world evidence from South America and highlight the need for prospective studies to refine patient selection.
PMID:
42376485
Bibliographic data and abstract were imported from PubMed on 30 Jun 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0